These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 11692936)

  • 1. [Local screening program for prostate cancer].
    Kotsev R; Kolev N; Stratev S; Mikhailov O
    Khirurgiia (Sofiia); 2000; 56(5-6):52-4. PubMed ID: 11692936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Results of a screening program for prostatic cancer].
    Martín Oses E; Luján Galán M; Sánchez Sánchez E; Herrero Payo A; Páez Borda A; Berenguer Sánchez A
    Actas Urol Esp; 1999 Apr; 23(4):287-95. PubMed ID: 10394648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
    Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
    BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of prostatic carcinoma: the role of TRUS, TRUS guided biopsy, digital rectal examination, PSA and PSA density.
    Men S; Cakar B; Conkbayir I; Hekimoglu B
    J Exp Clin Cancer Res; 2001 Dec; 20(4):473-80. PubMed ID: 11876539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Digital rectal examination as a prostate cancer-screening method in a country with a low incidence of prostate cancer.
    Shim HB; Lee SE; Park HK; Ku JH
    Prostate Cancer Prostatic Dis; 2007; 10(3):250-5. PubMed ID: 17297501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening for prostate cancer.
    Pode D; Shapiro A; Lebensart P; Meretyk S; Katz G; Barak V
    Isr J Med Sci; 1995; 31(2-3):125-8. PubMed ID: 7538101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Screening of cancer of the prostate: study in a Spanish population].
    Herrero Payo JA; Montes Díaz MJ; Páez Borda A; Sánchez Sánchez E; Moreno Valle JA; Berenguer Sánchez A
    Arch Esp Urol; 1996; 49(6):595-606. PubMed ID: 8929102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Percent free PSA as an additional measure in a prostate cancer screen.
    Miele ME
    Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparison between 2 techniques of screening for prostatic carcinoma. Rectal exploration and transrectal ultrasonography vs. prostate specific antigen].
    Ciatto S; Bonardi R; Mazzotta A; Lombardi C; Santoni R; Cardini S; Zappa M
    Radiol Med; 1994 Oct; 88(4):453-7. PubMed ID: 7527916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests.
    Mäkinen T; Tammela TL; Hakama M; Stenman UH; Rannikko S; Aro J; Juusela H; Määttänen L; Auvinen A
    J Urol; 2001 Oct; 166(4):1339-42. PubMed ID: 11547069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale for using serum prostate-specific antigen (PSA) level and PSA density (PSAD) to detect prostatic malignancy in a country with low prostate cancer incidence.
    Rahardjo D; Kamil ST; Pakasi LS
    Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():563-70. PubMed ID: 10895211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of percent free PSA for prostate cancer detection in men with a total PSA of 4-10 ng/ml.
    Bermúdez-Tamayo C; Martín Martín JJ; González Mdel P; Pérez Romero C
    Urol Int; 2007; 79(4):336-44. PubMed ID: 18025853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic performance of malignant prostatic cells detection in blood for early detection of prostate cancer: comparison to prostatic biopsy.
    Murray NP; Reyes E; Tapia P; Orellana N; Dueñas R; Fuentealba C; Badinez L
    Arch Esp Urol; 2011 Dec; 64(10):961-71. PubMed ID: 22228894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Normal range prostate-specific antigen versus age-specific prostate-specific antigen in screening prostate adenocarcinoma.
    el-Galley RE; Petros JA; Sanders WH; Keane TE; Galloway NT; Cooner WH; Graham SD
    Urology; 1995 Aug; 46(2):200-4. PubMed ID: 7542822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of the digital rectal examination in subsequent screening visits in the European randomized study of screening for prostate cancer (ERSPC), Rotterdam.
    Gosselaar C; Roobol MJ; Roemeling S; Schröder FH
    Eur Urol; 2008 Sep; 54(3):581-8. PubMed ID: 18423977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of prostate cancer in aging males receiving PSA (prostate specific antigen) screening test (A campaign for celebration of Siriraj Established Day).
    Srinualnad S; Charoenkraikamol C; Toraksa S; Uiprasertkul M; Amornvesukit T; Taweemonkongsap T; Udompunturak S; Nualyong C; Tantiwong A
    J Med Assoc Thai; 2006 Jan; 89(1):37-42. PubMed ID: 16583579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population.
    Bangma CH; Rietbergen JB; Kranse R; Blijenberg BG; Petterson K; Schröder FH
    J Urol; 1997 Jun; 157(6):2191-6. PubMed ID: 9146612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Diagnosis of localized prostate cancer: screening and preoperative staging].
    Hammerer P; Huland H
    Urologe A; 1991 Nov; 30(6):378-86. PubMed ID: 1722921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A performance analysis of the presence of malignant circulating prostate cells as a predictive factor for the detection of prostate cancer in the first, second and third prostate biopsy.
    Murray NP; Reyes E; Tapia P; Badinez L; Orellana N; Fuentealba C; Olivares R; Dueñas R
    Arch Esp Urol; 2013 May; 66(4):335-41. PubMed ID: 23676536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population-based screening for prostate cancer by measuring total serum prostate-specific antigen in Iran.
    Hosseini SY; Moharramzadeh M; Ghadian AR; Hooshyar H; Lashay AR; Safarinejad MR
    Int J Urol; 2007 May; 14(5):406-11. PubMed ID: 17511722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.